Regeneron Pharmaceuticals, Inc. $REGN is Lmcg Investments LLC’s 10th Largest Position

Lmcg Investments LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,979 shares of the biopharmaceutical company’s stock after selling 842 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.8% of Lmcg Investments LLC’s holdings, making the stock its 10th biggest position. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $30,117,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $29,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $31,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 4.1%

Regeneron Pharmaceuticals stock opened at $676.23 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $537.45 and a one year high of $821.11. The business’s fifty day moving average is $648.64 and its 200 day moving average is $724.11. The stock has a market capitalization of $71.49 billion, a PE ratio of 16.48, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $8.22 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on REGN. Truist Financial cut their target price on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a research note on Tuesday. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Canaccord Genuity Group decreased their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $790.46.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron to buy from hold, signaling improved confidence in the stock’s outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist kept a buy rating and reiterated a new price target of $769, suggesting meaningful upside from current levels despite a slight target cut. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC also maintained a buy rating after trimming its target to $880, reinforcing the view that analysts still see room for gains. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock and noted its favorable earnings surprise history, which may be building investor confidence ahead of the next report. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada lowered its target to $696 and kept a sector perform rating, which is a more cautious signal but still implies modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Jim Cramer’s comments that biotech could become “the hottest group in the market” added sector-wide optimism, but this was a broad industry call rather than Regeneron-specific news. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 transaction, which can sometimes weigh on sentiment even though the sale was relatively small. SEC filing for director sale
• Negative Sentiment: Cantor Fitzgerald and RBC both trimmed their price targets this week, suggesting analysts have slightly more tempered expectations for near-term upside. Regeneron price target changes

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.